Woodford Investment Management WIM and Neil Woodford

Neil Woodford: In the next five to 10 years those treatments for diabetes, cardio-vascular diseases and cancer will have to be approaching the market and showing revenue returns. , according to BBC. Others take the opposing view. Neil Woodford, who launched Woodford Investment Management WIM after a long and much lauded career at Invesco Perpetual, is one of the UK s most influential fund managers. As a major shareholder in BAE, he was instrumental in blocking its merger with the European aircraft giant, As part of their successful defence against Pfizer, the business presented bold decade-long forecasts about their drugs development - the now famous "pipeline". Investors are split over whether AstraZeneca s rapid rejection of each of Pfizer s advances were handled in the right way. Some, Like Axa and Jupiter, believe that the British-Swedish firm should have spoken in greater detail to their shareholders. One source close to Pfizer told me that AstraZeneca s share price would not see 55 the final offer from the US business "for a decade". ignificant risk Start Quote I will make more money for my investors by AstraZeneca remaining independent End Quote Neil Woodford Woodford Investment Management (news.financializer.com). As reported in the news.